Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Review of the novelties presented at the 27th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) (II).
The synthetic cannabinoid R(+)WIN55,212-2 augments interferon-β expression via peroxisome proliferator-activated receptor-α
Receptos Initiates SUNBEAM Phase 3 Trial of RPC1063 in Relapsing Multiple Sclerosis
Daclizumab Therapy for Multiple Sclerosis.
Pregnancy outcomes in patients exposed to interferon beta-1b.
Accentia Biopharmaceuticals Conducts Investigator Meeting in Preparation for New Multiple Sclerosis Drug Study for Cyrevia™
Impact of sleep disorder treatment on fatigue in multiple sclerosis.
BTG plc Close Period Update
Federation of Clinical Immunology Societies 2012
Efficacy and Tolerability of BAF312 in Patients With Polymyositis
Altered likelihood of brain activation in attention and working memory networks in patients with multiple sclerosis: An ALE meta-analysis.
Toxicity of Teriflunomide in Aryl Hydrocarbon Receptor Deficient Mice.
Tumefactive demyelination and a malignant course in an MS patient during and following fingolimod therapy.
IgE-Mediated Allergic Reactions after the First Administration of Glatiramer Acetate in Patients with Multiple Sclerosis.
Vitamin D and multiple sclerosis: epidemiology, immunology, and genetics.
TGN1412: From Discovery to Disaster.
Stem cells in autoimmune diseases: Implications for pathogenesis and future trends in therapy.
Th17 cells: A prognostic marker for MS rebound after natalizumab cessation?
Value and Efficacy of Transcranial Direct Current Stimulation in the Cognitive Rehabilitation: A Critical Review Since 2000.
Genzyme’s Lemtrada Approved by the FDA
Immune response during interferon beta-1b treatment in patients with multiple sclerosis who experienced relapses and those who were relapse-free in the START study.
Minocycline inhibits antigen processing for presentation to human T cells: additive inhibition with chloroquine at therapeutic concentrations.
Sample-size calculations for short-term proof-of-concept studies of tissue protection and repair in multiple sclerosis lesions via conventional clinical imaging
Tumefactive Multiple Sclerosis presenting as Acute Ischemic Stroke.
Receptos announces issuance of composition of matter patents covering proprietary lead product candidate RPC1063

Pages